[{"id":"c9fa59c0-ee9b-4c5f-baf7-8f04f47fe653","acronym":"","url":"https://clinicaltrials.gov/study/NCT05630794","created_at":"2022-11-30T18:57:52.049Z","updated_at":"2025-02-25T13:41:21.187Z","phase":"Phase 1","brief_title":"Testing ONC201 to Prevent Colorectal Cancer","source_id_and_acronym":"NCT05630794","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2 • IL6 • TNFA • IL10 • CASP3 • GZMA • IL17A • PRL","pipe":"","alterations":" ","tags":["BCL2 • IL6 • TNFA • IL10 • CASP3 • GZMA • IL17A • PRL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Modeyso (dordaviprone)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 03/30/2025","start_date":" 03/30/2025","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2028","study_completion_date":" 01/01/2028","last_update_posted":"2025-02-21"},{"id":"3aa72670-9b0b-4205-9807-1cc48204caf9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05335941","created_at":"2022-04-20T16:53:38.622Z","updated_at":"2025-02-25T15:35:35.713Z","phase":"Phase 2","brief_title":"A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma","source_id_and_acronym":"NCT05335941","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" MTAP • IL17A","pipe":"","alterations":" ","tags":["MTAP • IL17A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pemetrexed • Yutuo (zimberelimab) • etrumadenant (AB928)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/13/2023","start_date":" 06/13/2023","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2025-02-10"},{"id":"15ea0b15-7362-42f9-a5c9-83b6fa5b6dd1","acronym":"","url":"https://clinicaltrials.gov/study/NCT02451982","created_at":"2021-01-18T11:45:29.420Z","updated_at":"2025-02-25T14:35:37.102Z","phase":"Phase 2","brief_title":"Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas","source_id_and_acronym":"NCT02451982","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" CD8 • PD-1 • TNFRSF9 • GZMB • IL17A","pipe":"","alterations":" ","tags":["CD8 • PD-1 • TNFRSF9 • GZMB • IL17A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cyclophosphamide • BMS-986253 • GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) • cyclophosphamide intravenous • urelumab (BMS-663513)"],"overall_status":"Recruiting","enrollment":" Enrollment 76","initiation":"Initiation: 03/28/2016","start_date":" 03/28/2016","primary_txt":" Primary completion: 08/31/2025","primary_completion_date":" 08/31/2025","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2024-12-06"},{"id":"2d9a8f08-c565-475d-9d28-781aa1dd5529","acronym":"","url":"https://clinicaltrials.gov/study/NCT06662006","created_at":"2025-02-26T07:54:41.562Z","updated_at":"2025-02-26T07:54:41.562Z","phase":"Phase 2","brief_title":"Nal-IRI/5-FU/LV Chemotherapy Combined with PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT As Second-line Therapy in Metastatic Pancreatic Cancer Patients","source_id_and_acronym":"NCT06662006","lead_sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","biomarkers":" IFNG • IL6 • TNFA • IL2 • IL10 • IL17A • IFNA1 • IL1B","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • IL2 • IL10 • IL17A • IFNA1 • IL1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • Focus V (anlotinib) • Andewei (benmelstobart) • Onivyde (nanoliposomal irinotecan)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 10/01/2024","start_date":" 10/01/2024","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-10-28"},{"id":"3385c8c2-d2a8-4dfb-904b-d2b81538ee4e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06599710","created_at":"2025-02-26T14:44:18.610Z","updated_at":"2025-02-26T14:44:18.610Z","phase":"","brief_title":"The Effects of a Food Product Containing Mushroom Extracts (AndoSanTM) in Subjects with Colorectal Cancer-related Fatigue","source_id_and_acronym":"NCT06599710","lead_sponsor":"Mycotech Pharma AS","biomarkers":" IL6 • TNFA • IL10 • IL17A","pipe":"","alterations":" ","tags":["IL6 • TNFA • IL10 • IL17A"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 09/09/2024","start_date":" 09/09/2024","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2024-09-20"},{"id":"7d9b53ef-b645-44ee-9c8e-8c8c3875b0f3","acronym":"","url":"https://clinicaltrials.gov/study/NCT06569485","created_at":"2025-02-26T12:22:38.642Z","updated_at":"2025-02-26T12:22:38.642Z","phase":"Phase 2","brief_title":"A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma Patients","source_id_and_acronym":"NCT06569485","lead_sponsor":"Sun Yat-sen University","biomarkers":" CD8 • IFNG • CDK4 • IL2RA • CD4 • IL2 • FOXP3 • IL17A • ISG20","pipe":"","alterations":" ","tags":["CD8 • IFNG • CDK4 • IL2RA • CD4 • IL2 • FOXP3 • IL17A • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Cosela (trilaciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 05/23/2024","start_date":" 05/23/2024","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-08-26"},{"id":"f457b6dc-bf69-44d9-a56c-049a2a1cb232","acronym":"","url":"https://clinicaltrials.gov/study/NCT02111941","created_at":"2024-01-03T19:17:22.178Z","updated_at":"2024-07-02T16:34:38.080Z","phase":"Phase 1","brief_title":"Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer","source_id_and_acronym":"NCT02111941","lead_sponsor":"Mayo Clinic","biomarkers":" IFNG • TNFA • IL10 • GZMB • IL17A","pipe":"","alterations":" ","tags":["IFNG • TNFA • IL10 • GZMB • IL17A"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 19","initiation":"Initiation: 04/14/2014","start_date":" 04/14/2014","primary_txt":" Primary completion: 07/27/2021","primary_completion_date":" 07/27/2021","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-06-05"},{"id":"64411eb8-6d74-4c88-b0b8-fb08d1f38b31","acronym":"","url":"https://clinicaltrials.gov/study/NCT02210117","created_at":"2021-01-18T10:21:09.236Z","updated_at":"2024-07-02T16:34:59.480Z","phase":"Phase 1","brief_title":"Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery","source_id_and_acronym":"NCT02210117","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IL17A","pipe":"","alterations":" ","tags":["IL17A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Avastin (bevacizumab) • Yervoy (ipilimumab) • Beianting (bevacizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 104","initiation":"Initiation: 11/25/2014","start_date":" 11/25/2014","primary_txt":" Primary completion: 11/30/2025","primary_completion_date":" 11/30/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2024-06-03"},{"id":"c1b27e69-5cb6-4c7f-a2c7-df42fb2ed239","acronym":"CYTOK-AZA","url":"https://clinicaltrials.gov/study/NCT06439199","created_at":"2024-06-08T04:34:20.475Z","updated_at":"2024-07-02T16:34:59.405Z","phase":"","brief_title":"Biological, Prospective Study Evaluating the Dosage of Plasma Cytokines Including the FLT3 Ligand and IL6 of Patients Treated With Non-intensive Chemotherapy","source_id_and_acronym":"NCT06439199 - CYTOK-AZA","lead_sponsor":"Nantes University Hospital","biomarkers":" IL6 • TNFA • CXCL8 • IL10 • CSF2 • IL18 • IL17A • IL15 • IL1B","pipe":"","alterations":" ","tags":["IL6 • TNFA • CXCL8 • IL10 • CSF2 • IL18 • IL17A • IL15 • IL1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 06/15/2024","start_date":" 06/15/2024","primary_txt":" Primary completion: 04/15/2026","primary_completion_date":" 04/15/2026","study_txt":" Completion: 12/15/2026","study_completion_date":" 12/15/2026","last_update_posted":"2024-06-03"},{"id":"f003bb6c-5459-49c1-947d-35ec28b1d2c8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04135079","created_at":"2024-02-23T15:25:03.657Z","updated_at":"2024-07-02T16:35:04.833Z","phase":"","brief_title":"Immune Profiling in Multiple Myeloma","source_id_and_acronym":"NCT04135079","lead_sponsor":"Mario Boccadoro","biomarkers":" PD-1 • IFNG • IL6 • TNFA • IL2RA • ICOS • IL10 • CD27 • ICOSLG • TGFB1 • CD31 • IL17A • IL1B • PECAM1 • CD86","pipe":"","alterations":" ","tags":["PD-1 • IFNG • IL6 • TNFA • IL2RA • ICOS • IL10 • CD27 • ICOSLG • TGFB1 • CD31 • IL17A • IL1B • PECAM1 • CD86"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 04/15/2019","start_date":" 04/15/2019","primary_txt":" Primary completion: 04/28/2021","primary_completion_date":" 04/28/2021","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2024-05-08"},{"id":"d69e14be-12ab-4d05-911e-0e6d60227602","acronym":"CATCH","url":"https://clinicaltrials.gov/study/NCT04188912","created_at":"2021-01-18T20:25:07.418Z","updated_at":"2024-07-02T16:35:09.852Z","phase":"","brief_title":"Close Assessment and Testing for Chronic Graft Versus Host Disease, CATCH Study","source_id_and_acronym":"NCT04188912 - CATCH","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" IFNG • IL6 • IL2 • IL10 • FOXP3 • IL17A • IL1B","pipe":"","alterations":" ","tags":["IFNG • IL6 • IL2 • IL10 • FOXP3 • IL17A • IL1B"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 09/13/2019","start_date":" 09/13/2019","primary_txt":" Primary completion: 08/31/2025","primary_completion_date":" 08/31/2025","study_txt":" Completion: 08/31/2025","study_completion_date":" 08/31/2025","last_update_posted":"2024-04-12"},{"id":"10599d1b-ab63-473c-8b0c-5bf751c350b9","acronym":"","url":"https://clinicaltrials.gov/study/NCT02812420","created_at":"2021-01-18T13:47:40.933Z","updated_at":"2024-07-02T16:35:12.340Z","phase":"Phase 1","brief_title":"Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery","source_id_and_acronym":"NCT02812420","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IL17A","pipe":"","alterations":" ","tags":["IL17A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 03/07/2017","start_date":" 03/07/2017","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-03-29"},{"id":"59264190-7a26-482a-8591-2a0bf535a2e7","acronym":"NCI-2018-02517","url":"https://clinicaltrials.gov/study/NCT03744793","created_at":"2021-01-18T18:20:30.566Z","updated_at":"2024-07-02T16:35:16.094Z","phase":"Phase 2","brief_title":"Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer","source_id_and_acronym":"NCT03744793 - NCI-2018-02517","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" MTAP • IL17A","pipe":"","alterations":" ","tags":["MTAP • IL17A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Bavencio (avelumab) • pemetrexed"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 04/11/2019","start_date":" 04/11/2019","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 01/31/2025","study_completion_date":" 01/31/2025","last_update_posted":"2024-03-06"},{"id":"fce6af2b-5318-4afa-9d41-cc377d3baf65","acronym":"MICRO-MM","url":"https://clinicaltrials.gov/study/NCT05712967","created_at":"2023-02-06T16:02:54.862Z","updated_at":"2024-07-02T16:35:16.893Z","phase":"","brief_title":"Role of the Host Microbiota and Il-17 in Favoring Multiple Myeloma Progression","source_id_and_acronym":"NCT05712967 - MICRO-MM","lead_sponsor":"IRCCS San Raffaele","biomarkers":" IL17A","pipe":"","alterations":" ","tags":["IL17A"],"overall_status":"Completed","enrollment":" Enrollment 62","initiation":"Initiation: 06/14/2019","start_date":" 06/14/2019","primary_txt":" Primary completion: 02/05/2024","primary_completion_date":" 02/05/2024","study_txt":" Completion: 02/05/2024","study_completion_date":" 02/05/2024","last_update_posted":"2024-03-01"},{"id":"a01dd9f5-a287-4b7c-81c3-e982628b8af0","acronym":"","url":"https://clinicaltrials.gov/study/NCT06199947","created_at":"2024-01-11T22:20:15.626Z","updated_at":"2024-07-02T16:35:23.958Z","phase":"","brief_title":"Study of the Role of Oncostatin M in Head and Neck Squamous Cell Carcinoma","source_id_and_acronym":"NCT06199947","lead_sponsor":"Poitiers University Hospital","biomarkers":" IL6 • TNFA • IL10 • IL17A • IL1B","pipe":"","alterations":" ","tags":["IL6 • TNFA • IL10 • IL17A • IL1B"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 119","initiation":"Initiation: 02/01/2024","start_date":" 02/01/2024","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-01-10"},{"id":"03f0ece7-ebce-42e4-9045-500e01cc7916","acronym":"","url":"https://clinicaltrials.gov/study/NCT06152367","created_at":"2023-11-30T18:15:50.315Z","updated_at":"2024-07-02T16:35:27.607Z","phase":"Phase 1/2","brief_title":"Immunization With Autologous Dendritic Cells and Tumor Lysates in Melanoma Patients","source_id_and_acronym":"NCT06152367","lead_sponsor":"University of Chile","biomarkers":" IFNG • TNFA • IL10 • IL17A","pipe":" | ","alterations":" IL10 elevation","tags":["IFNG • TNFA • IL10 • IL17A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IL10 elevation"],"overall_status":"Completed","enrollment":" Enrollment 90","initiation":"Initiation: 01/30/2001","start_date":" 01/30/2001","primary_txt":" Primary completion: 10/09/2004","primary_completion_date":" 10/09/2004","study_txt":" Completion: 10/09/2004","study_completion_date":" 10/09/2004","last_update_posted":"2023-11-30"},{"id":"98b71e20-18b4-4643-a7a1-0a9a241a26a3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05406531","created_at":"2022-06-06T12:57:29.839Z","updated_at":"2024-07-02T16:35:32.617Z","phase":"","brief_title":"The Effectiveness of Psychological Interventions in Psycho-neuroendocrine-immune Network in Breast Cancer Survivors","source_id_and_acronym":"NCT05406531","lead_sponsor":"Masaryk University","biomarkers":" CD8 • IL6 • IL2 • NCAM1 • IL10 • CD14 • IL17A • CRP","pipe":"","alterations":" ","tags":["CD8 • IL6 • IL2 • NCAM1 • IL10 • CD14 • IL17A • CRP"],"overall_status":"Recruiting","enrollment":" Enrollment 440","initiation":"Initiation: 06/06/2022","start_date":" 06/06/2022","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2023-10-19"},{"id":"001c58b3-679e-474b-89ca-d4d2f94dabda","acronym":"","url":"https://clinicaltrials.gov/study/NCT04275154","created_at":"2021-01-18T20:45:50.532Z","updated_at":"2024-07-02T16:35:39.484Z","phase":"","brief_title":"Immunological Parameters, Neurocognitive Changes, Activity, \u0026 Driving Fitness in Patients Undergoing CAR-T Cell Therapy","source_id_and_acronym":"NCT04275154","lead_sponsor":"University of Nebraska","biomarkers":" IFNG • IL6 • TNFA • IL2 • IL10 • IL17A • IL4","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • IL2 • IL10 • IL17A • IL4"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/01/2020","start_date":" 09/01/2020","primary_txt":" Primary completion: 05/25/2021","primary_completion_date":" 05/25/2021","study_txt":" Completion: 05/25/2021","study_completion_date":" 05/25/2021","last_update_posted":"2023-08-21"},{"id":"9ae4eede-f757-4258-926b-cb6caf976257","acronym":"","url":"https://clinicaltrials.gov/study/NCT05967533","created_at":"2023-08-01T16:10:23.357Z","updated_at":"2024-07-02T16:35:41.462Z","phase":"Phase 1","brief_title":"The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors","source_id_and_acronym":"NCT05967533","lead_sponsor":"University of California, Davis","biomarkers":" CD8 • IFNG • IL6 • IL2RA • CD4 • CD69 • IL2 • IL10 • LAMP1 • TGFB1 • FOXP3 • IL17A • ISG20","pipe":" | ","alterations":" IFNG expression","tags":["CD8 • IFNG • IL6 • IL2RA • CD4 • CD69 • IL2 • IL10 • LAMP1 • TGFB1 • FOXP3 • IL17A • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IFNG expression"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 06/02/2023","start_date":" 06/02/2023","primary_txt":" Primary completion: 06/02/2025","primary_completion_date":" 06/02/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-08-01"},{"id":"c15a52de-3419-47f0-9b51-09f2e18386cc","acronym":"","url":"https://clinicaltrials.gov/study/NCT05964985","created_at":"2023-07-31T17:08:51.096Z","updated_at":"2024-07-02T16:35:41.679Z","phase":"","brief_title":"Effect of Quadratus Lumborum Block With Compound Lidocaine and Esketamine on Pain After Colorectal Surgery","source_id_and_acronym":"NCT05964985","lead_sponsor":"Tianjin Medical University General Hospital","biomarkers":" CCL2 • IL18 • IL17A • IL23A • CXCL1","pipe":"","alterations":" ","tags":["CCL2 • IL18 • IL17A • IL23A • CXCL1"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 08/06/2023","start_date":" 08/06/2023","primary_txt":" Primary completion: 01/15/2024","primary_completion_date":" 01/15/2024","study_txt":" Completion: 02/15/2024","study_completion_date":" 02/15/2024","last_update_posted":"2023-07-28"},{"id":"1d76bd59-1106-4b42-9f95-8ec48f34176c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05366569","created_at":"2022-05-09T11:56:31.025Z","updated_at":"2024-07-02T16:35:42.352Z","phase":"","brief_title":"Bio-CAR-T BS Study","source_id_and_acronym":"NCT05366569","lead_sponsor":"Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia","biomarkers":" IL6 • IL2 • IL10 • FAP • IL17A • IL23A • IL22 • GFAP","pipe":"","alterations":" ","tags":["IL6 • IL2 • IL10 • FAP • IL17A • IL23A • IL22 • GFAP"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 04/26/2022","start_date":" 04/26/2022","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2023-07-21"},{"id":"47205faa-8c1e-46a2-b3dd-b675260ad752","acronym":"PROFIT","url":"https://clinicaltrials.gov/study/NCT05938504","created_at":"2023-07-10T13:08:58.402Z","updated_at":"2024-07-02T16:35:43.541Z","phase":"","brief_title":"Usefulness of Balanced High Protein Supplementation on Recovery and Clinical Outcomes After Chemotherapy","source_id_and_acronym":"NCT05938504 - PROFIT","lead_sponsor":"Daesang Wellife","biomarkers":" IFNG • IL6 • TNFA • IL2 • IL10 • IL17A","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • IL2 • IL10 • IL17A"],"overall_status":"Recruiting","enrollment":" Enrollment 154","initiation":"Initiation: 03/14/2023","start_date":" 03/14/2023","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 02/28/2025","study_completion_date":" 02/28/2025","last_update_posted":"2023-07-10"},{"id":"8bfb48a5-7a5e-4365-8828-e51c1648bb77","acronym":"ATPIC","url":"https://clinicaltrials.gov/study/NCT05867004","created_at":"2023-05-19T13:04:57.952Z","updated_at":"2024-07-02T16:35:47.091Z","phase":"","brief_title":"Blocking TNF to Potentiate the ICI-dependent Immune Awakening in Melanoma","source_id_and_acronym":"NCT05867004 - ATPIC","lead_sponsor":"Institut Claudius Regaud","biomarkers":" CD8 • IFNG • CD4 • CD14 • CD68 • FOXP3 • IL17A","pipe":" | ","alterations":" HLA-A2 positive","tags":["CD8 • IFNG • CD4 • CD14 • CD68 • FOXP3 • IL17A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A2 positive"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 01/01/2023","start_date":" 01/01/2023","primary_txt":" Primary completion: 11/30/2023","primary_completion_date":" 11/30/2023","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2023-05-26"},{"id":"c18a797f-f388-457a-8936-39bcb7181e0b","acronym":"MyBrain","url":"https://clinicaltrials.gov/study/NCT05840575","created_at":"2023-05-03T15:04:43.419Z","updated_at":"2024-07-02T16:35:49.160Z","phase":"","brief_title":"Investigating Cognitive Impairment in Young Patients With Cancer Prospectively","source_id_and_acronym":"NCT05840575 - MyBrain","lead_sponsor":"Rigshospitalet, Denmark","biomarkers":" IL6 • TNFA • IL10 • IL17A • BDNF • GFAP • NEFL","pipe":"","alterations":" ","tags":["IL6 • TNFA • IL10 • IL17A • BDNF • GFAP • NEFL"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 03/01/2022","start_date":" 03/01/2022","primary_txt":" Primary completion: 03/01/2027","primary_completion_date":" 03/01/2027","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2023-05-02"}]